Some CRPCs may develop into treatment-related neuroendocrine prostate cancer (t-NEPC), which is characterized by neuroendocrine carcinoma morphology, expression of neuroendocrine markers, loss of AR expression and independence of AR signaling [6,7]. The gene discussed is AR; the disease is neuroendocrine carcinoma.